ArticleNature immunology2019
Activation of naïve CD4
Open access · greenAbstract read
In one paragraph
Article in Nature immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 51 citations in OpenAlex.
- Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.Nature reviews. Drug discovery · 2026Review
- Interleukin-6 stimulates platelet 12-lipoxygenase to drive coagulation in inflammatory arthritis.Journal of lipid research · 2026Article
- Adipocyte-derived LTB4 programs human NKG2AJournal for immunotherapy of cancer · 2026Article
- Mechanisms, functions and therapeutic targeting of protein tyrosine phosphatases.Nature reviews. Molecular cell biology · 2026Review
- Transcriptomic rewiring of the JAK-STAT pathway in circulating CD4Frontiers in immunology · 2026Article
- Investigation of complex miRNA-mRNA interaction networks during JAK inhibitor therapy in rheumatoid arthritis.Frontiers in pharmacology · 2026Article
- Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach.Biomedicines · 2025Article
- Article
- Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritis.BMC rheumatology · 2025Article
- Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.Journal of hematology & oncology · 2025Article
- Article
- Precision Prediction of Alzheimer's Disease: Integrating Mitochondrial Energy Metabolism and Immunological Insights.Journal of molecular neuroscience : MN · 2025Article
- Effect of compound polysaccharide on immunity, antioxidant capacity, gut microbiota, and serum metabolome in kittens.Frontiers in microbiology · 2025Article
- Phenotypic consequences of logarithmic signaling in MAPK stress response.bioRxiv : the preprint server for biology · 2023Article
- Age-dependent transcriptomic profiles of leukocytes in pediatric population.Clinical immunology (Orlando, Fla.) · 2023Article
- Th1 Cells Alter the Inflammatory Signature of IL-6 by Channeling STAT Transcription Factors to Alu-like Retroelements.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Interferon regulatory factor 1 (IRF1) inhibits lung endothelial regeneration following inflammation-induced acute lung injury.Clinical science (London, England : 1979) · 2023Article
- The Role of Oxidative Inactivation of Phosphatase PTEN and TCPTP in Fatty Liver Disease.Antioxidants (Basel, Switzerland) · 2023Review
- T-helper cells flexibility: the possibility of reprogramming T cells fate.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 5 institutions in 2 countries.
Jason P TwohigDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Ana Cardus FiguerasDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.ORCID http://orcid.org/0000-0003-4699-6205
Robert AndrewsSystems Immunity University Research Institute, Cardiff University, Cardiff, UK.
Florian WiedeMonash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Benjamin C CossinsDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Alicia Derrac SoriaDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Myles J LewisCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary's School of Medicine & Dentistry, London, UK.ORCID http://orcid.org/0000-0001-9365-5345
Michael J TownsendBiomarker Discovery OMNI, Genentech Research & Early Development, South San Francisco, CA, USA.
David MillrineDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.ORCID http://orcid.org/0000-0002-8041-0151
Jasmine LiMonash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
David G HillDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Javier Uceda FernandezDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Xiao LiuDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Barbara SzomolayDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Christopher J PepperDivision of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK.ORCID http://orcid.org/0000-0003-3603-8839
Philip R TaylorDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.ORCID http://orcid.org/0000-0003-0163-1421
Costantino PitzalisCentre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Queen Mary's School of Medicine & Dentistry, London, UK.ORCID http://orcid.org/0000-0003-1326-5051
Tony TiganisMonash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
Nigel M WilliamsDivision of Psychological Medicine & Clinical Neuroscience, School of Medicine, Cardiff University, Cardiff, UK.
Gareth W JonesDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Simon A JonesDivision of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK. JonesSA@cf.ac.uk.ORCID http://orcid.org/0000-0001-7297-9711
Cardiff University · GBAustralian Regenerative Medicine Institute · AUWilliam Harvey Research Institute · GBBrighton and Sussex Medical School · GBUniversity of Bristol · GB
Funding
Medical Research Council G0800648Medical Research Council MR/L010305/1Versus Arthritis 19796Versus Arthritis 20022Versus Arthritis 20305Versus Arthritis 20770Wellcome Trust 069630Wellcome Trust 107964Worldwide Cancer Research 12-1172
Abstract
The cytokine IL-6 controls the survival, proliferation and effector characteristics of lymphocytes through activation of the transcription factors STAT1 and STAT3. While STAT3 activity is an ever-present feature of IL-6 signaling in CD4
Indexed as
Signal TransductionAnimalsArthritis, RheumatoidCD4-Positive T-LymphocytesCells, CulturedCHO CellsCricetulusGene Expression RegulationHumansImmunologic MemoryInterleukin-6Lymphocyte ActivationMaleMiceMice, Inbred C57BLMice, KnockoutInterleukin-6Protein Tyrosine Phosphatase, Non-Receptor Type 2PTPN2 protein, humanPtpn2 protein, mouseReceptors, Antigen, T-CellReceptors, Interleukin-6Stat1 protein, mouseSTAT1 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.